价格60/千中文
请完成试译后发我邮箱，并附上联系方式
On 02 Aug 2011 (Study Day 7), a laboratory work up showed WBC count 1.96 x 109/L and platelet count 68 x 109/L, and the patient was diagnosed with non serious Grade 3 WBC count decreased and Grade 3 platelet count decreased. Relevant laboratory tests are shown in the table below. He received treatment with rutin, herbal, homeopathic and dietary supplements, recombinant human thrombopoietin (rhTPO), and oprelvekin for platelet count decreased, whereas no treatment was given for WBC count decreased. On 07 Aug 2011 (Study Day 12), the event of white blood cell count decreased resolved without sequelae (WBC count for this date was not reported). On 09 Sep 2011 (Study Day 45), his platelet count was 92 x 109/L, and the event of Grade 3 platelet count decreased resolved without sequelae. The gemcitabine dose was modified from 2,025 mg to 1,510 mg and cisplatin from 120 mg to 90 mg.
On 23 Sep 2011 (Study Day 59, Cycle 2, Day 9), the patient was diagnosed with a non serious Grade 4 event of platelet count decreased (platelet count on this date was not reported). He received rhTPO for this event. On 11 Oct 2011 (Study Day 77), the event of Grade 4 platelet count decreased resolved without sequelae (platelet count to this date was not reported). Prior to event onset of Grade 4 platelet count decreased, his last cycle (Cycle 2) of cisplatin was administered on 14 Sep 2011 (Study Day 50) and of gemcitabine on 21 Sep 2011 (Study Day 57) which were also the last doses during the study. He had received four doses of gemcitabine and two doses of cisplatin during the study. Dose of the last cycle (Cycle 2) of gemcitabine was 1,510 mg and of cisplatin was 90 mg.
--
FROM 122.236.35.*